Final 5-Year Follow-Up of a Randomized Controlled Trial of @entity2239 - and @entity1311 -Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of XXXX -Eluting Stents and @entity1311 Stents for Coronary Revascularization in Daily Practice).

@entity1 @entity1311 @entity2239 @entity583 @entity204 @entity715
OBJECTIVES: This study sought to report the 5-year outcomes of @entity2239 -eluting stents (EES) and @entity1311 -eluting stents (PES) in an all-comers population undergoing percutaneous coronary intervention (PCI). BACKGROUND: The medium-term 1 and 2-year results of the prospective randomized COMPARE trial (A Trial of @entity2239 -Eluting Stents and @entity1311 -Eluting Stents for Coronary Revascularization in Daily Practice) showed superior clinical outcomes with EES compared with PES in an all-comers PCI population. Whether this benefit is sustained over longer-term follow-up is unknown. Furthermore, systematic long-term follow-up data on these metallic drug eluting stents with durable polymers are scarce. METHODS: We randomly assigned 1,800 @entity1 undergoing PCI to EES or PES. The pre-specified composite primary endpoint was @entity204 , @entity583 ( @entity583 ), or target vessel revascularization (TVR). RESULTS: Follow-up at 5 years was completed in 1,791 (99.5%) @entity1 . Treatment with EES compared with PES led to a relative risk reduction of the primary endpoint by 27% (18.4% vs. 25.1%, p = 0.0005), driven by lower rates of @entity583 (7.0% vs. 11.5%, p = 0.001) and TVR (7.4% vs. 11.4%, p = 0.003), but not with mortality (9.0% vs. 10.3%, relative risk 0.88, p = 0.36). Moreover, @entity1 treated with EES compared with PES had lower rates of definite/probable stent @entity715 at 5 years (3.1% vs. 5.9%, p = 0.005). The hazard curves for TVR, @entity583 , and stent @entity715 diverge over the first 3 years and, subsequently, progress in parallel. CONCLUSIONS: The early- and medium-term superiority of EES over PES measured both by safety and efficacy endpoints is sustained at 5 years in this all-comer population. (A Trial of @entity2239 -Eluting Stents and @entity1311 -Eluting Stents for Coronary Revascularization in Daily Practice [COMPARE]; NCT01016041).
